These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 17539747)

  • 1. Drug metabolite profiling and elucidation of drug-induced hepatotoxicity.
    Tang W
    Expert Opin Drug Metab Toxicol; 2007 Jun; 3(3):407-20. PubMed ID: 17539747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic bioactivation and drug-related adverse effects: current status and future directions from a pharmaceutical research perspective.
    Tang W; Lu AY
    Drug Metab Rev; 2010 May; 42(2):225-49. PubMed ID: 19939207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic activation in drug-induced liver injury.
    Leung L; Kalgutkar AS; Obach RS
    Drug Metab Rev; 2012 Feb; 44(1):18-33. PubMed ID: 21939431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxicophores: investigations in drug safety.
    Williams DP
    Toxicology; 2006 Sep; 226(1):1-11. PubMed ID: 16860917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
    Sakatis MZ; Reese MJ; Harrell AW; Taylor MA; Baines IA; Chen L; Bloomer JC; Yang EY; Ellens HM; Ambroso JL; Lovatt CA; Ayrton AD; Clarke SE
    Chem Res Toxicol; 2012 Oct; 25(10):2067-82. PubMed ID: 22931300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatotoxicity and hepatic metabolism of available drugs: current problems and possible solutions in preclinical stages.
    Giri S; Nieber K; Bader A
    Expert Opin Drug Metab Toxicol; 2010 Aug; 6(8):895-917. PubMed ID: 20367107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reactive Metabolites: Current and Emerging Risk and Hazard Assessments.
    Thompson RA; Isin EM; Ogese MO; Mettetal JT; Williams DP
    Chem Res Toxicol; 2016 Apr; 29(4):505-33. PubMed ID: 26735163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selection of new chemical entities with decreased potential for adverse drug reactions.
    Park KB; Dalton-Brown E; Hirst C; Williams DP
    Eur J Pharmacol; 2006 Nov; 549(1-3):1-8. PubMed ID: 16979156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of metabolic activation in drug-induced hepatotoxicity.
    Park BK; Kitteringham NR; Maggs JL; Pirmohamed M; Williams DP
    Annu Rev Pharmacol Toxicol; 2005; 45():177-202. PubMed ID: 15822174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabonomics for discovering biomarkers of hepatotoxicity and nephrotoxicity.
    Zhang A; Sun H; Wang P; Han Y; Wang X
    Pharmazie; 2012 Feb; 67(2):99-105. PubMed ID: 22512077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro evaluation of potential hepatotoxicity induced by drugs.
    Gómez-Lechón MJ; Lahoz A; Gombau L; Castell JV; Donato MT
    Curr Pharm Des; 2010 Jun; 16(17):1963-77. PubMed ID: 20236064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detecting reactive drug metabolites for reducing the potential for drug toxicity.
    Grillo MP
    Expert Opin Drug Metab Toxicol; 2015; 11(8):1281-302. PubMed ID: 26005795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of metabolism in drug-induced idiosyncratic hepatotoxicity.
    Walgren JL; Mitchell MD; Thompson DC
    Crit Rev Toxicol; 2005; 35(4):325-61. PubMed ID: 15989140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting toxicities of reactive metabolite-positive drug candidates.
    Kalgutkar AS; Dalvie D
    Annu Rev Pharmacol Toxicol; 2015; 55():35-54. PubMed ID: 25292426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Idiosyncratic toxicity: the role of toxicophores and bioactivation.
    Williams DP; Park BK
    Drug Discov Today; 2003 Nov; 8(22):1044-50. PubMed ID: 14690635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic activation and drug-induced liver injury: in vitro approaches for the safety risk assessment of new drugs.
    Gómez-Lechón MJ; Tolosa L; Donato MT
    J Appl Toxicol; 2016 Jun; 36(6):752-68. PubMed ID: 26691983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Reactive metabolites of xenobiotics : their role in the hepatotoxicity of drugs].
    Pessayre D; Benhamou JP
    C R Seances Soc Biol Fil; 1979; 173(2):458-68. PubMed ID: 159767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug bioactivation, covalent binding to target proteins and toxicity relevance.
    Zhou S; Chan E; Duan W; Huang M; Chen YZ
    Drug Metab Rev; 2005; 37(1):41-213. PubMed ID: 15747500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Important role of proinflammatory cytokines/other endogenous substances in drug-induced hepatotoxicity: depression of drug metabolism during infections/inflammation states, and genetic polymorphisms of drug-metabolizing enzymes/cytokines may markedly contribute to this pathology.
    Prandota J
    Am J Ther; 2005; 12(3):254-61. PubMed ID: 15891270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective Application of Metabolite Profiling in Drug Design and Discovery.
    Cerny MA; Kalgutkar AS; Obach RS; Sharma R; Spracklin DK; Walker GS
    J Med Chem; 2020 Jun; 63(12):6387-6406. PubMed ID: 32097005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.